ULIPRISTAL ACETATE: NEW POSSIBILITIES IN THE TREATMENT OF UTERINE LEIOMYOMA
- Autores: TIKHOMIROV A.L1, KAZENASHEV V.V1
-
Afiliações:
- A.I. Evdokimov Moscow State University of Medicine and Dentistry
- Edição: Nº 9 (2013)
- Páginas: 97-100
- Seção: Articles
- URL: https://journals.eco-vector.com/0300-9092/article/view/247069
- ID: 247069
Citar
Texto integral
Acesso aberto
Acesso está concedido
Acesso é pago ou somente para assinantes
Resumo
Uterine myoma is the most common cause of hysterectomy, but contemporary patients prefer to avoid removal of the womb and to preserve fertility and femininity that they associate this organ with. In recent decade, the proved role of progesterone in stimulating the growth of uterine leiomyoma has aroused interest in the study of a possibility for the treatment of this disease with selective progesterone receptor modulators. The decrease in the sizes of uterine myoma, regardless of its baseline dimensions, due to performed therapy with ulipristal acetate maintains for at least 6 months after completing a course of treatment. Menstrual blood loss reduces from profuse bleeding with clots to moderate one and to the point of amenorrhea. At this stage, the indication for the use of ulipristal acetate 5 mg daily is preoperative therapy for the moderate and severe symptoms of uterine myoma in adult reproductive-aged women above 18 years of age with the investigated treatment duration of not more 3 months. This review gives the results of studying the efficacy and safety of ulipristal acetate in the treatment of uterine myoma and describes new possible prospects for use of ulipristal acetate in gynecology.
Palavras-chave
Texto integral
Sobre autores
A. TIKHOMIROV
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: tikhomiroval@yandex.ru
V. KAZENASHEV
A.I. Evdokimov Moscow State University of Medicine and Dentistry
Email: vkazenashev@mail.ru
Bibliografia
- Levy B.S. Management of uterine fibroids. Acta Obstet. Gynecol. Scand. 2008; 87(8): 812-23.
- Practice Committee of American Society for Reproductive Medicine in collaboration with Society of Reproductive Surgeons. Myomas and reproductive function. Fertil. Steril. 2008; 90(5, Suppl.): S125-30.
- Somigliana E., Vercellini P., Daguati R., Pasin R., De Giorgi O., Crosignani P.G. Fibroids and female reproduction: a critical analysis of the evidence. Hum. Reprod. Update. 2007 ;13: 465-76.
- Yin P., Lin Z., Reierstad S., Wu J., Ishikawa H., Marsh E.E. et al. Transcription factor KLF11 integrates progesterone receptor signaling and proliferation in uterine leiomyoma cells. Cancer Res. 2010; 70(4): 1722-30.
- Kim J.J., Sefton E.C. The role of progesterone signaling in the pathogenesis of uterine leiomyoma. Mol. Cell. Endocrinol. 2012; 358(2): 223-31.
- Lethaby A., Vollenhoven B., Sowter M. Pre-operative GnRH analogue therapy before hysterectomy or myomectomy for uterine fibroids. Cochrane Database Syst. Rev. 2001; (2): CD000547.
- Campo S., Garcea N. Laparoscopic myomectomy in premenopausal women with and without preoperative treatment using gonadotrophin-releasing hormone analogues. Hum. Reprod. 1999; 14: 44-8.
- Тихомиров А.Л., Леденкова А.А. Доброкачественные гиперплазии матки и внутриматочная левоноргестрел-релизинг система. Гинекология. 2012; 3: 62-4.
- Zapata L.B., Whiteman M.K., Tepper N.K., Jamieson D.J., Marchbanks P.A., Curtis K.M. Intrauterine device use among women with uterine fibroids: a systematic review. Contraception. 2010; 82: 41-55.
- Sayed G.H., Zakhera M.S., El-Nashar S.A., Shaaban M.M. A randomized clinical trial of a levonorgestrel-releasing intrauterine system and a low-dose combined oral contraceptive for fibroid-related menorrhagia. Int. J. Gynaecol. Obstet. 2011; 112: 126-30.
- Spitz I.M. Clinical utility of progesterone receptor modulators and their effect on the endometrium. Curr. Opin. Obstet. Gynecol. 2009; 21: 318-24.
- Mutter G.L., Bergeron C., Deligdisch L., Ferenczy A., Glant M., Merino M. et al. The spectrum of endometrial pathology induced by progesterone receptor modulators. Mod. Pathol. 2008; 21(5): 591-8.
- Ioffe O.B., Zaino R.J., Mutter G.L. Endometrial changes from short-term therapy with CDB-4124, a selective progesterone receptor modulator. Mod. Pathol. 2009; 22: 450-9.
- Levens E.D., Potlog-Nahari C., Armstrong A.Y., Wesley R., Premkumar A., Blithe D.L. et al. CDB-2914 for uterine leiomyomata treatment: a randomized controlled trial. Obstet. Gynecol. 2008; 111(5): 1129-36.
- Nieman L.K., Blocker W., Nansel T., Mahoney S., Reynolds J., Blithe D. et al. Efficacy and tolerability of CDB-2914 treatment for symptomatic uterine fibroids: a randomized, double-blind, placebo-controlled, phase IIb study. Fertil. Steril. 2011; 95(2): 767-72; e1-2.
- Chabbert-Buffet N., Meduri G., Bouchard P., Spitz I.M. Selective progesterone receptor modulators and progesterone antagonists: mechanisms of action and clinical applications. Hum. Reprod. Update. 2005; 11: 293-307.
- Spitz I.M. Progesterone antagonists and progesterone receptor modulators: an overview. Steroids. 2003; 68: 981-93.
- Attardi B.J., Burgenson J., Hild S.A., Reel J.R., Blye R.P. CDB-4124 and its putative monodemethylated metabolite, CDB-4453, are potent antiprogestins with reduced antiglucocorticoid activity: in vitro comparison to mifepristone and CDB-2914. Mol. Cell. Endocrinol. 2002; 188: 111-23.
- Attardi B.J., Burgenson J., Hild S.A., Reel J.R. In vitro antiprogestational/antiglucocorticoid activity and progestin and glucocorticoid receptor binding of the putative metabolites and synthetic derivatives of CDB-2914, CDB-4124, and mifepristone. J. Steroid Biochem. Mol. Biol. 2004; 88: 277-88.
- Gainer E.E., Ulmann A. Pharmacologic properties of CDB(VA)-2914. Steroids. 2003; 68: 1005-11.
- Yoshida S., Ohara N., Xu Q., Nakabayashi K., Sasaki H., Morikawa A. et al. Celltype specific actions of progesterone receptor modulators in the regulation of uterine leiomyoma growth. Semin. Reprod. Med. 2010; 28(3): 260-73.
- Chabbert-Buffet N., Pintiaux-Kairis A., Bouchard P.; VA2914 Study Group. Effects of the progesteron receptor modulator VA2914 in continuous low dose on the hypothalamic-pituitary-ovarian axis and endometrium in normal women: a prospective, randomized, placebo-controlled trial. J. Clin. Endocrinol. Metab. 2007; 92(9): 3582-9.
- Donnez J., Tatarchuk T.F., Bouchard P., Puscasiu L., Zakharenko N.F., Ivanova T. et al.; PEARL I Study Group. Ulipristal acetate versus placebo for fibroid treatment before surgery. N. Engl. J. Med. 2012; 366(5): 409-20.
- Donnez J., Tomaszewski J., Vázquez F.,BouchardP., Lemiesz-czuk B., Baró F. et al.; PEARL I Study Group. Ulipristal acetate versus leuprolide acetate for uterine fibroids. N. Engl. J. Med. 2012; 366(5) : 421-32.
- Тихомиров А.Л. Миома, патогенетическое обоснование органосохраняющего лечения. Монография. М.; 2013. 319с.
- Preglem. Data on file: PGL 4001 Ulipristal acetate investigator’s brochure. Edition 7. 2013. Data on file: PGL 4001 Ulipristal acetate investigator’s brochure. 7th ed. 2013.
Arquivos suplementares
